Author:
Allos Beshar,Fernando Indrajit N.,Walji Nawaz
Publisher
Springer International Publishing
Reference21 articles.
1. Winter WE 3rd, Maxwell GL, Tian C, et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;94(2):495–501.
2. Fernandes DCR, Andreyev HJN. Gastrointestinal toxicity of pelvic radiotherapy: are we letting women down? Clin Oncol. 2021;S0936-6555(21):00166–7.
3. Mazeron R, Castelnau-Marchand P, Dumas I, et al. Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiother Oncol. 2015;114(2):257–63.
4. Klopp AH, Yeung AR, Deshmukh S, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018;36(24):2538–44.
5. Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018;1(1):CD012529.